Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: jopawa who wrote (1058)	2/2/1999 9:09:00 PM
From: Anthony Wong	Respond to of 2539

An interesting post from TMF Monanto thread: boards.fool.com

To: jopawa who wrote (1058)	2/2/1999 9:12:00 PM
From: Anthony Wong	Respond to of 2539

Will's Drug Stock Commentary from labpuppy.com: 2/2/99 PaineWebber raised its target price on Pfizer (PFE) to $156 (from $140) due to the strength of Celebrex. Pfizer is co-promoting this product with Monsanto (MTC). Celebrex new prescriptions in its second week on the market climbed an additional 45,500 (on top of 9,500 in its first week). This product is showing tremendous growth. PaineWebber also raised Merck (MRK) to an Attractive rating from Neutral due to its low valuation and because of the strength of Celebrex (which means that its Vioxx product should do well). labpuppy.com